Julius Strauss, M.D.

Julius Strauss, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Center for Immuno-Oncology


Dr. Strauss is a Staff Clinician (physician) in the Center for Immuno-Oncology (CIO). He is Clinical Director of CIO Combination Immunotherapy Group. His clinical research is focused on the use of novel agents capable of inducing the immune system to recognize and kill cancer cells. Dr. Strauss is very interested in the use of these agents in combination with each other as well as "standard" cytotoxic therapies in an effort to improve their efficacy. Dr. Strauss also has an interest in using these therapies to help patients with the fewest treatment options, including patients with rare diseases.

Areas of Expertise

1) immunotherapy 2) therapeutic cancer vaccines 3) immune checkpoint inhibitors

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.


Selected Key Publications

Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.
Clin Cancer Res.. 24: 1287-95, 2018.
Full-Text Article
[ Journal Article ]

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus–associated malignancies

Strauss J, Gatti-Mays M, Cho BC, Hil A, Salas S, McClay E, Redman J, Abdul Sater H, Donahue R, Jochems C, Lamping E, Burmeister A, Marté J, Cordes L, Bilusic M, Karzai F, Ojalvo L, Jehl G, Rolfe PA, Hinrichs CS, Madan R, Schlom J, Gulley JL
J ImmunoTher Cancer. 8(2): e001395, 2020.
Full-Text Article
[ Journal Article ]

First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors

Strauss J, Heery CR, Kim J, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL
Clin Cancer Res. 25(1): 99-109, 2019.
Full-Text Article
[ Journal Article ]

A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules

Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman J, Madan RA, Marté JN, Cordes L, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL
Clin Cancer Res. 25(16): 4933-4944, 2019.
Full-Text Article
[ Journal Article ]

A phase I trial using a multi-targeted recombinant Ad5 (CEA/MUC1/Brachyury)–based immunotherapy vaccine regimen in patients with advanced cancer

Gatti-Mays ME, Redman JM, Donahue RN, Palena C, Madan RA, Karzai F, Bilusic M, Sater HA, Marté JL, Cordes LM, McMahon S, Steinberg SM, Orpia A, Burmeister A, Schlom J, Gulley JL, Strauss J
Oncologist. 25(6): 479-e899, 2020.
Full-Text Article
[ Journal Article ]


Bonnie L. Casey
Patient Care Coordinator (Contr.)
Cynthia Moye
Patient Care Coordinator (Contr.)
Camilo Pacheco Puentes
Physician Assistant
Lauren Skeffington, M.S.


In Viewpoint: Evolving Issues in Oncology: “Vaccines as an integral component of cancer immunotherapy,” Drs. Jeffrey Schlom and James Gulley describe the opportunities and challenges for vaccine therapies to treat cancers. JAMA. 2018 Dec 4;320(21):2195-2196.

Immunotherapy drug with two targets shows promise against HPV-related cancers. In a Phase 1 clinical trial at the NCI of 43 patients with advanced cancers, the investigational immunotherapy drug bintrafusp alfa shrank the tumors of some patients with advanced human papillomavirus (HPV)-related cancers. “This drug is a promising agent for patients with HPV-related cancers and may potentially benefit these patients more than traditional checkpoint therapies,” said the trial's Principal Investigator, Julius Strauss, M.D., Laboratory of Tumor Immunology and Biology, CCR, NCI. [NCT02517398]

Clinical trial tests immunotherapy combination for advanced HPV-ssociated cancers. Dr. Julius Strauss is leading a study using a combination of 3 immunotherapy drugs to treat HPV+ cancers. [NCT04287868]

New trial evaluates immunotherapy combinations in adults with advanced small bowel and colorectal cancers is being led by Dr. Julius Strauss. [NCT04491955]

Clinical trial will test triple-drug combination against aggressive colon and HPV-associated cancers. Dr. Julius Strauss discusses promising immunotherapy drug for patients with HPV-related cancers. [NCT04708470]

CCR plays key role in first FDA-approved drug for treatment of Merkel cell carcinoma